Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 4

Tolvaptan, hyponatremia, and heart failure

Authors Zmily H, Daifallah S, Ghali J

Published 31 March 2011 Volume 2011:4 Pages 57—71

DOI https://doi.org/10.2147/IJNRD.S7032

Review by Single anonymous peer review

Peer reviewer comments 2



Hammam D Zmily1, Suleiman Daifallah2, Jalal K Ghali3
1
Wayne State University/Detroit Medical Center, Detroit, MI, USA; 2John D Dingell VA Medical Center, Detroit, MI, USA; 3Detroit Medical Center, Detroit, MI, USA

Abstract: Tolvaptan is the first FDA-approved oral V2 receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan inhibits the binding of arginine vasopressin to the V2 receptors on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion of water. This article reviews the accumulated experience with tolvaptan and all the major clinical trials that were conducted to study its safety and efficacy and concludes by summarizing clinicians’ views of its current application in clinical practice.

Keywords: arginine vasopressin antagonist, tolvaptan, heart failure, hyponatremia

 

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.